GlaxoSmithKline said on Monday a late-stage study testing its initial maintenance therapy, Zejula, in patients with ovarian cancer who have undergone platinum-based chemotherapy showed positive results.
GlaxoSmithKline said on Monday a late-stage study testing its initial maintenance therapy, Zejula, in patients with ovarian cancer who have undergone platinum-based chemotherapy showed positive results.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
